Dyadic International (NASDAQ:DYAI) Stock Price Passes Below Fifty Day Moving Average of $1.36

Dyadic International, Inc. (NASDAQ:DYAI) passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $1.36 and traded as low as $1.22. Dyadic International shares last traded at $1.23, with a volume of 7,944 shares traded.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Dyadic International in a research report on Monday, July 8th.

Dyadic International Trading Down 0.8 %

The stock has a market capitalization of $35.96 million, a PE ratio of -4.39 and a beta of 0.74. The stock’s 50 day moving average price is $1.36 and its 200-day moving average price is $1.57. The company has a quick ratio of 5.39, a current ratio of 5.39 and a debt-to-equity ratio of 1.72.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The firm had revenue of $0.39 million during the quarter, compared to the consensus estimate of $1.00 million. Dyadic International had a negative return on equity of 145.95% and a negative net margin of 428.86%. During the same period in the prior year, the company posted ($0.07) EPS. On average, sell-side analysts expect that Dyadic International, Inc. will post -0.26 earnings per share for the current fiscal year.

Institutional Trading of Dyadic International

A hedge fund recently raised its stake in Dyadic International stock. Chapin Davis Inc. raised its stake in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 847,301 shares of the biotechnology company’s stock after buying an additional 21,000 shares during the quarter. Chapin Davis Inc. owned about 2.90% of Dyadic International worth $1,254,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.